Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
:FGEN
FGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.50 - $38.25
Previous CloseN/A
Volume937.77K
Average Volume (3M)43.79K
Market Cap
$23.08M
Enterprise Value$1.43B
Total Cash (Recent Filing)$33.61M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 11, 2025EPS Estimate
-2.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding4,041,759
10 Day Avg. Volume74,528
30 Day Avg. Volume43,787
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-69.90
Price to Sales (P/S)0.00
P/FCF Ratio-8.12
Enterprise Value/Market Cap62.11
Enterprise Value/Revenue5.34
Enterprise Value/Gross Profit-105.38
Enterprise Value/Ebitda-2.52
Forecast
1Y Price Target
$10.00Price Target Upside88.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
FibroGen News
PremiumCompany Announcements
FibroGen Enters New Agreement with HiFiBiO
PremiumCompany Announcements
FibroGen Announces Reverse Stock Split Effective June 16
PremiumCompany Announcements
FibroGen Amends Financing Agreement for Flexibility
PremiumCompany Announcements
FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes
Bulls Say, Bears Say
Bulls Say
Financial PositionThe anticipated extension of the company's cash runway strengthens its overall current and future financial health.
Research And DevelopmentFibroGen remains focused on advancing FG-3246, with upcoming studies that provide multiple shots on goal.
Strategic TransactionsThe sale of FibroGen China to AstraZeneca is considered a strategic transaction, providing FibroGen with additional capital and streamlining its portfolio.
Bears Say
Financial PenaltiesAnnounced a settlement related to roxadustat, which will result in a $1.25 million civil penalty paid to FibroGen.
Pipeline SetbacksThe focus remains on Pamrevlumab, especially after the latest Roxa setback, indicating continued strategic pipeline development.
Regulatory ChallengesManagement conveyed that interactions with the FDA have progressed in a timely manner with no delays, despite investor uncertainties.
Ownership Overview
1.57% Insiders
10.40% Mutual Funds
13.04% Other Institutional Investors
70.24% Public Companies and Individual Investors
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $4.50 and its highest was $38.25 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $23.08M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Aug 11, 2025 which is in 44 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on May 12, 2025. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.5.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -2.25.
How many shares outstanding does FibroGen have?
FibroGen has 4,041,759 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of $1.25 in its last earnings report, beating expectations of $0.75. Following the earnings report the stock price went down -2.094%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (88.68% Upside)
$10.00 (88.68% Upside)
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 35.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.90%
12-Months-Change
Fundamentals
Return on Equity
60.38%
Trailing 12-Months
Asset Growth
-54.84%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. is a biopharmaceutical company primarily focused on the discovery, development, and commercialization of therapeutic solutions for serious unmet medical needs. The company specializes in fibrosis and hypoxia-inducible factor (HIF) biology, with its core products targeting anemia, fibrotic disease, and cancer. FibroGen operates within the biotechnology sector and is headquartered in San Francisco, California.
FGEN Company Deck
FGEN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a transformative period for FibroGen, with the sale of FibroGen China to AstraZeneca bringing in higher than expected proceeds and extending their financial runway significantly. There is notable progress in their clinical pipeline, particularly in the development of FG-3246 and FG-3180, with promising results from clinical trials. However, the company faced a significant decline in revenue and continued to operate at a net loss. While the highlights indicate strategic advancements and positive financial prospects, the revenue decline and continued net loss are concerning.Read More>FGEN Stock 12 Month Forecast
Average Price Target
$10.00
▲(88.68%Upside)